As an AD-selective DEG eliminated by CBD treatment, Cplx2 (Nie et al., 2021) also modulates neuronal control of memory in patients with schizophrenia (Hass et al., 2015) and during frontotemporal dementia (FTD) pathogenesis (Ramos-Miguel et al., 2018). This evidence concerns the gene CPLX2 and frontotemporal dementia.